Purpose Three-dimensional (3D) printing has received significant attention as a manufacturing process for pharmaceutical dosage forms. In this study, we used Fusion Deposition Modelling (FDM) in order to print Bcandy -like^formula-tions by imitating Starmix® sweets to prepare paediatric medicines with enhanced palatability. Methods Hot melt extrusion processing (HME) was coupled with FDM to prepare extruded filaments of indomethacin (IND), hypromellose acetate succinate (HPMCAS) and polyethylene glycol (PEG) formulations and subsequently feed them in the 3D printer. The shapes of the Starmix® objects were printed in the form of a heart, ring, bottle, ring, bear and lion. Differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), Fourier Transform Infra-red Spectroscopy (FT-IR) and confocal Raman analysis were used to assess the drug -excipient interactions and the content uniformity. Results Physicochemical analysis showed the presence of molecularly dispersed IND in the printed tablets. In vivo taste masking evaluation demonstrated excellent masking of the drug bitterness. The printed forms were evaluated for drug dissolution and showed immediate IND release independently of the printed shape, within 60 min. Conclusions 3D printing was used successfully to process drug loaded filaments for the development of paediatric printed tablets in the form of Starmix® designs. 
INTRODUCTION
The development of high quality, effective and safe paediatric medicines has been proven a challenging process for the pharmaceutical industry. Due to the substantial differences inthe drug development process for paediatric patients and adult patients, new regulations were introduced by the European Medicines Agency (EMEA) in 2007, which governed the drug production strategies for paediatric medications. According to Strickley et al. (2007) development difficulties are related to dose modification, ease of administration/swallowing, taste masking, physical stability, packaging and providing/ designing the measuring device [1] .
The oral route of administration is often utilized as the route of choice for the delivery of medical products to paediatric patients, in both solid and liquid forms including;syrups, suspensions and emulsions; powders, granules, effervescent tablets, orodispersible tablets, chewable tablets and gums; mini tablets, innovative granules; andboth conventional immediate release and modified release tablets and capsules [2] . A great disadvantage of liquid medications is the higher chance of error when measuring dosagefor self-administration. A number of studies have demonstrated that patients who self administer liquid medications have anestimated error rate of 50% to 60%, due to their inability to measure the correct dose [3] [4] [5] . This problem can be avoided by manufacturing solid oral dosage forms which offer a number advantages over the liquid forms, these include; having a lower cost of development, easy administration, greater stability, dose accuracy, have the capacity to develop modified release formulations, can be produced with greater uniformity and have greater taste masking capabilities [6] .Although oral administration is the most common route for paediatric populations, the development of palatable formulations is complicated. The developed medicines should be easily swallowed, taste masked while maintaining safety, efficacy, accessibility and affordability. Nevertheless, there is an increased demand for the development of novel technologies for paediatric patients that mainly focus on the formulation design and/or administration/dosing devices [7] .
Such a novel technology is 3D printing, which encompasses a wide range of additive manufacture processes, where products are designed using Computer Aided Design (CAD) software [8] [9] [10] [11] . The product is then processed by a slicing software that divides the object into thin cross sections. These are then printed out one on top of the other, forming compact layers which form the 3D structure. The primary objective of the various 3D printing technologies is to develop and produce models and prototypes of the designed product in a rapid and inexpensive manner [12] . The epitome of 3D printing applications for medicinal products is the recently approved 3D printed drug product called Spritam (levetiracetam) manufactured by using the Zipdose Technology based on a powder bed-liquid 3D printing technology.
An increasing number of researchers are employing 3D printing technologies to develop oral dosage forms, with modified drug release profiles to allow either sustained or immediate drug release [13] [14] [15] .Recently, 3D printing was utilized to create a multi-active solid dosage form, containing 5 different API compartmentalised within the same capsule, which are autonomouslycontrolled with two separate release profiles, called Polypill [16] . An interesting approach was presentedbyGoyannes et al. where an anti-acne drug (salicylic acid) loaded structure in the shape of a nose was prepared by comparing Fused Deposition Modelling (FDM) and stereolithography [17] .
However, FDM has proven to be one of the more versatile 3D printing methods due to the range of potential printing materials, which can be utilized on the system. However, further development of FDM extruders have allowedfor the printing of almost any thermoplastic material such as polycarbonate and polyurethane [18] . Recently, the utilisation of FDM was extended to pharmaceutical materials where filaments of drugs and polymers are prepared and extruded through an FDM 3D printer. Specifically, FDM has been utilised to prepare formulations of differing shapes and infill ratio'sin order totune the drug release profile [19, 20] . As expected tablets weights increased with an increasing infill percentage and same size, demonstrating high reproducibility in physical dimensions, along with high mechanical strength which is resistant to damage upon handling. Moreover, extended release tablet of prednisolone were fabricated by using loaded poly(vinyl alcohol) (PVA) filaments [21] .The precision of dose control ranged between 88.7% and 107%whileprednisolone existed in amorphous form within the PVA matrix and released from the 3D printed tablet over a 24 h period. Other work involves the development of Patient-Specific Immediate Release Tablets using theophylline loaded filaments as a mixture with PVP in the presence of plasticiser produced by means of hot melt extrusion. A 3D printing technique was applied to produce caplet-shaped tablets with excellent mechanical properties and an immediate in-vitro release pattern [22] .The aforementioned examplesdemonstrate that by simply modifying the printing patterns and structure, without altering the polymer-drug properties, it is possible to modify the drug dissolution rates.
The aim of this work was to introduce the feasibility of 3D printing coupled with hot melt extrusion to prepare paediatric medicines that can be consumed easily by childrenfrom2-11 years old. The medicines were designed in such a way to imitate Bsweet -like^chewable tablets. Chewable tablets are a valuable paediatric dosage form and have been used for various products such as antacids, antibiotics, anticonvulsants, analgesics, antiasthmatics and cold/allergy preparations. The proposed 3D printing approach improves compliance and adherence of children to the prescribed medication. In addition the combined HME and 3D printing benefits such as taste masking and easy to swallow respectively, lead to dose accuracy and enhanced palatability. For the purposes of the study BStarmix®^(HARIBO PLC, UK) designs were printed using IND as model drug substance and HMPCAS as the polymeric excipient. Indomethacin is a nonsteroidal antiinflammatory drug commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation and HPMCAS is a thermoplastic polymer which has been used primarily as an enteric coating material and dissolves at pH 5.5-6.8.
MATERIALS AND METHODS

Materials
Indomethacin (IND) and polyethylene glycol (PEG)were purchased from Tokyo Chemicals (Belgium) and Sigma -Aldrich ( U . K . ) r e s p e c t i v e l y . H y p r o m e l l o s e a c e t a t e succinate(HPMCAS, AQOAT AS-MF)was kindly donated by Shin -Etsu (Japan).
Extrusion of IND -HPMCAS Filament
A physical blend composed of indomethacin, HPMCAS and PEG 6000 at 20/60/20wt/wt ratio were accurately weighed and homogeneously blended in a Turbula shaker-mixer at 100 rpm for 10 min. The blended physical mixer was loaded into a DD Flexwall 18 feeder (Brabender Technology, Germany), and fed into a twin-screw extruder (Eurolab 16, Thermo Fisher, Germany) at a rate of 10 g per minute. A circular shaped die was employed to yield polymer strand extrudates. The 9 heating zones across the barrel were set at the following temperature profile; 40°C, 55°C, 75°C, 100°C, 140°C, 140°C, 140°C, 140°C, 120°C with the die temperature set at 80°C. The barrel was slightly cooled towards the end to allow the mixture to re-solidify, ensuring the endproduct was extruded as a strand, which is uniform in diameter. A screw speed of 50 rpm was utilised.
3D Printing Process of Paediatric Formulations
The Starmix®structures were printed by using a standard FDM printer HD2xR Airwolf (U.S.A). The structures were designed with SolidWorks (Dassault Systems, USA) and exported as .stl files which were subsequently imported into Cura software to generate the Gcode for the printing. The print temperature was 165°C and the print speed was set at 25 mm/s. The infill percentage was 7% and the layer height 150 μm. The size of the perimeter shell was 0.5 mm and the top and bottom shell 0.4 mm. No supports or rafts were utilised in the printed model.
Scanning Electron Microscopy (SEM)
The morphology of the extruded polymer strands and the 3D printed structure was observed via scanning electron microscopy (Hitachi SU8030, Japan). Both Samples were placed on an aluminium stub and coated with a thin layer of Mikrostik nonconductive adhesive (Agar scientific, UK). The samples were then plated with chromium under an atmosphere of argon. SEM images were taken using an electron beam accelerating voltage of 2 kV. Images were captured between ×30 and 2.00 k magnifications.
X-Ray Powder Diffraction (XRPD)
X-ray powder diffraction was used to determine the solid state of the bulk materials, the extruded polymer strand and the polymer strand after 3D Printing. This was done using a D8 advanced x-ray Diffractometer (Bruker, Germany) in reflection mode. A Cu anode X-ray tube was powered at 40 kV and 40 mA. A primary Göbel mirror was used for the parallel beam and the removal of CuKβ. A primary 4 o Soller slit, a secondary 2.5 o Soller slit and a 0.6 mm exit slit was selected for this experiment. Each sample was scanned from 2 to 60°2θ with a step size of 0.02°2θ degrees/step and a counting time of 0.2 s/step. As the polymer samples were difficult to crush to a small enough size to run for XRPD, they were first doused in liquid nitrogen then ground in a mortar and pedestal, before being placed in a low background holder and inserted into the device. DIFFRAC.EVA software was used for the phase analysis.
Differential Scanning Calorimetry (DSC)
The temperature profiles of the bulk ingredients and extruded strands were analysed using a differential scanning calorimeter (Mettler-Toledo 823e, Greifensee, Switzerland). The samples were accurately weighed between 3 mg-5 mg and placed into an aluminium pan and crimped. Each sample was heated from 0°C to 300°C at 10°C/min heating rate except for PEG 6000 which was heated to 150°C. Nitrogen gas was used as a purge, at a flow rate was set at 50 ml/min. STARe excellence software was used to analyse the data.
Fourier Transform Infra-Red Spectroscopy (FT-IR)
FTIR analysis was performed on the drug, carrier, drug/ carrier physical mixtures, and complex using PerkinElmer PE1600 (Massachusetts 02451, USA) Fourier transform infrared spectra according to the KBr disc method from 400 to 3600 wavelength/cm − 1 range.For FT-IR analysis, amorphous IND was prepared by using solvent evaporation method where IND dissolved in methanol following by rapid evaporation of the solvent.
Confocal Raman Analysis
Room temperature Raman spectra of the Bpure^formulation components were obtained using a Jobin/YvonLabRam 320 instrument equipped with an Olympus microscope (Horiba, Japan). The spectrometer is equipped with an 1800 grooves/ mm holographic grating, a holographic notch filter, a Peltiercooled CCD (MPP1 chip) for detection, and an Olympus BX40 microscope. An Ar + ion laser (λ = 633 nm) was used. Raman spectra of solid-state samples were collected at room temperature on a microscope slide using a microscope objective of 50× magnification to focus the laser beam. A backscattering (180°between excitation and collection) geometry was used in all experiments. Each spectral scan was collected for 5 s using 4 accumulations. The Raman instrument was calibrated using the v1 line of silicon at 520.7 cm −1 . Raman mapping was performed using a Jobin/ YvonLabRam 320 instrument equipped with an Olympus microscope (Horiba, Japan) by means of Ar + ion laser (λ = 532.8 nm) and 1800 l/nm grating on 3 different particles for each formulation. The experimental conditions were: 100 nm slit width, a 50× Microsoft objective and 0.4 s acquisition time. Each spectrum was the mean of the two. The sample profiling was performed at step increments of 3 μm in the X-Y direction covering the biggest possible surface of the part.Principal component analysis (PCA) was applied to identify the number of components and plot the chemical maps. Prior to analysis, the spectra baseline was checked by using the automatic weighted least square and normalised to theunit area to avoid deviation among the Raman spectra.
Taste Masking of 3D Designs
In vivo taste masking evaluation was performed on 10 healthy human volunteers from whom informed consent was first obtained (approved by the EthicsCommittee of the University of Greenwich). The study is also in accordance to the Code of Ethics of the World Medical Association (Declaration of Helsinki). The healthy volunteers of either sex (age [18] [19] [20] [21] [22] [23] [24] [25] were selected, trained and the one Stramix design was held in the mouth for another 120 s, and then spat out. The mouth was rinsed with water without swallowing the tablet. The equivalent of 50 mg of bulk IND was held in the mouth for 30 s and then spat out.Bitterness was recorded immediately to the bitterness intensity scale from 1 to 5 where 1, 2, 3, 4, and 5 indicate no, threshold, slight, moderate, and strong bitterness.
In Vitro Dissolution Studies
Dissolution studies were conducted by using a USP II paddle apparatus (Varian 705, US). The amount of extruded powders was equivalent to 25 mg of IND, placed into 900 mL of phosphate buffer solution (pH 6.8), in each dissolution vessel (n = 3). The temperature of the dissolution media was maintained at 37°C with a paddle rotation of 100 rpm. Samples, about 2-3 mL, were withdrawn at 10, 20, 30, 60, 90 and 120 min intervals and filtered with a 200 μm filter prior to HPLC analysis.
HPLC Analysis
The content of IND in dissolution samples was determined by HPLC. The samples were analysed on an HPLC system (Agilent Technologies, 1200 series) equipped with a quaternary pump using a Hichrom S50DS2-4889 (5 μm × 150 mm × 4 mm) column. The column temperature time was set at 25°C while the retention time was 4 min. The mobile phase consisted of 70:30:0.2 (v/v/v) methanol/water/acetic acid and the injected sample volumes were 20 μL, the flow rate was 1.5 mL/min, and the detector was set at a wavelength of 260 nm. The calibration curve for IND was plotted over a concentration range of 10-50 μg/mL.
RESULTS AND DISCUSSION
Hot Melt Extrusion (HME) and 3D Printing Coupling HME is a well-known processing pharmaceutical technology that has been successfully used over the past twenty years to increase thesolubility of water insoluble drugs and mask the taste of bitter APIs for paediatric applications by producing solid dispersions [23] . In this study, HME was employed as the core technique to produce printing filaments and subsequently coupled with a 3D printer. HME nowadays is the predominant technique to create filaments of pharmaceutical compounds which can be subsequentlyinsertedinto the 3D printer. The active pharmaceutical ingredient (API) is introduced either by soaking [24] or by extrusion [25] [26] [27] . IND was selected as a model API as it has been previously reported to produce extruded solid dispersions with increased solubility while HPMCAS is a suitable thermoplastic career for manufacturing of drug loaded strands. The main aim of the study was to manufacture taste masked IND/HPMCAS solid dispersions with increase drug solubility in the form of strands/filaments that could be fed to the 3D printer and produce paediatric chewable tablets. According to Lopez et al., the capability of children to swallow solid dosage forms is a major issue and thus chewable tablets are an excellent paediatric dosage form [3] . They can be administrated to children of 2 years old and older whereswallowing or disintegration is assisted by the patient.
The design of the chewable tablets was inspired by the Starmix flavour gummy sweets (HARIBO plc.) to appear as Bcandy -like^formulations. By imitating these popular confectionaries the 3D printed chewable tablets aim to improve patient compliance and palatability.
Process Optimisation
Premixed drug, polymer and plasticiser blends were fed into the extruderin order to produce drug-loaded filaments suitable for 3D printing. One of the most critical features is the filament quality, which should be flexible enough to prevent any breakage printing. For that purpose, PEG was added as aplasticiser to facilitate better extrusion processing and enhance the strand flexibility. Various polymer/plasticiser ratios were tested (data not shown) to concluded that 20% PEG was giving the best filament quality. The diameter of the filament was adjusted between 2.7 and2.9 mm, to meet the 3D printer specifications.Due to the HPMCAS/PEG swelling at the end of the extrusion process a die of 1 mm was selected to process the formulations.
As shown in Fig. 1 various Starmix®INDloaded structures were printed at a wide range of designs. By using SolidWorks the process was programmed with 5% infill ratio 25 mm s The 3D printing optimisation process was a prerequisite to achieving excellent bonding between the layers and thus fine 3D printed structures. All Starmix® structures were printed at temperatures of 165°C much higher than those used to extrude the exact same formulations. This can be explained by the effect of the extrusion process (e.g. screw configuration, temperature profile), which results in higher torque and consequently reduces significantly the melt viscosity of the extruded formulations. In addition, due to the small size of the 3D printing nozzle further temperature increase is required to reduce the melt viscosity of the filament and achieve the optimum printing conditions. Due to the complexity of the designs the weight of the individual printed forms was adjusted to deliver 50 mg of IND according to the initial drug/polymer ratio. The 3D printing of Starmix® designs was highly accurate, reproducible and produced smooth structures without any defects. Nevertheless, a weight and content uniformity variation of 5-10% was observed due the some inconsistencies of the filament thickness. The variations observed on tablet size were negligible.
Scanning Electron Microscopy
The topography of the filament and the 3D printed structure was investigated by means of SEM. As illustrated in Fig. 2a , the hot melt extruded filament presented a homogeneous and very smooth surface without any defects suggesting a perfect extrusion processing. No drug particles could be observed on the filament surface indicating very good IND blending and content uniformity (see further analysis). The manufacturing of high quality filaments is a prerequisite in order to facilitate robust 3D printing process with the required resolution of the printed designs. Figure 2c shows the layer by layer deposition of the printed layers which appear to be uniform with close packing. The thickness of the layerswereestimated at 150-180 μm.
Thermal Analysis
Thermogravimetric analysis (TGA) was used to examine the thermal stability of pharmaceutical ingredientsunder the hot melt extrusion and 3D printing processing temperatures. In Fig. 3 , IND showed that a negligible mass loss (0.5%) up to 170°C followed by a fast mass loss at around 220°C due to its degradation. AQOAT exhibited a small mass loss (2.7%) from 30 to 170°C and a second at 250°C which corresponds to its degradation. PEG was extremely stable at high temperatures without any losses and only presented a fast mass loss at 320°C due to its degradation. Both filament and the 3D printed Starmix structures demonstrates identicalmass loss pathways showing that all mixtures remain stable up to 250°C with 2.8% mass loss, which is higher than the degradation temperature of IND indicating interactions among the polymers and the drug substance. Above thistemperature, both samples exhibited afast mass loss due to degradation. Overall, theTGA profiles demonstrate that the HME filament is suitable for 3D printingtemperature at 165°C.
DSC was conducted to investigate the physicochemical properties of the bulk materials the extruded filament and the 3D structures. As shown in Fig. 4 , IND exhibits a strong endothermic peak at 160.99°C which is typical for the crystalline γ-form while PEG 6000 exhibits a melting endotherm at 62°C. HPMCAS is an amorphous polymer with a glass transition at 131°C while it presents an exothermic peak at 175°C indicating crystallisation followed by a degradation endothermic peak at 191.8°C. The extruded filament shows a melting endotherm at 52. 16 o corresponding to PEG 6000 melting point suppression while no IND melting endotherm can be observed suggesting that the drug is in amorphous or molecularly dispersed form. A thermal endotherm appears at 223.5°C which is probably related to the HPMCAS degradation. Interestingly, in the thermogram of the 3D printed structures the PEG 6000 melting endotherm has disappeared suggesting that the polymer has turned to its amorphous state due to the second thermal processing (3D extrusion).
X-Ray Diffraction Analysis
X-ray analysis was performed in order to verify the physical state of IND in the 3D printed designs. The XRD diffractogram of bulk IND, HPMCAS, filament and 3D printed are illustrated in Fig. 5 o 2θ values, which are indicative of PEG suggesting that a part of the plasticiser is still in thecrystallinestate. This observation is also in good agreement with the DSC analysis where the PEG melting endotherm was identified. In contrast,the diffractograms of the 3D printed structure did not reveal any intensity peaks and the two PEG peaks have disappeared indicatingthat PEG has turned to completely amorphous state. This was attributed to the effect of the filament re-heating during the printing process, which occurs at higher temperature compared to the HME process.
FT-IR Spectroscopy
FT-IR analysis of the extruded formulations and the 3D printed structures was used to examine possible interactions among the compounds. Specifically, the carbonyl groups (-CO) and hydroxyl group (-OH) of IND can form hydrogen bonds with the -OH and COOH groups of AQOAT respectively. Such interactions of IND have previously reported with saccharin [ 29] , polyvinyl pyrrolidon e [30] and hydroxypropyl-β-cyclodextrin [31] . The DSC and XRD analysis showed the presence of IND in amorphous form within the extruded filaments and printed structured. Therefore, amorphous IND was prepared in order to identify the related peak shifting compared to the crystalline form. Figure 6 demonstrates that crystalline of γ-form indomethacin containsbenzoyl and acid carbonyl groups corresponding at 1717 cm −1 and 1690 cm −1 respectively, whereas in amorphous form these peaks have moved towards lower wavenumbers at 1708 cm −1 (presence cyclic dimers) and 1680 cm −1 respectively. This observation is in good agreement with the published work by Taylor and Zografi [32] . In the 3D printed structure and filament the acid carbonyl group has moved to 1685 cm −1 whereas the benzoyl peak overlapped by the strong carbonyl peak of HPMCAS indicating H-bonding interactions.The amorphous state of IND in HPMC solid dispersions has also confirmed by other groups [33, 34] , and it is attributed to the molecular mobility of IND within the polymer matrix.Another interesting observation is that the carbonyl peak of HPMCAS has shifted towards lower wavenumbers from 1745 cm −1 to 1733 cm −1 only for the 3D printed structure. This is due to the additional heat processing of the filament, suggesting stronger H-bonding interactions of the IND/HPMCAS blend. Figure 7 shows the Raman spectra of the bulk compounds, extruded filament and 3D printed structures in the range of 1580 cm showed that the peak at 1702 cm −1 corresponds to benzoyl carbonyl vibration while the peaks associated with the symmetrical stretching vibrations of the cyclic dimer formed by the carboxyl groups are not active in the Raman spectra [32] . In amorphous IND the peak is shifted towards lower wavenumbers at 1684 cm
Raman Mapping
. In order to investigate the IND homogeneity within the printed structures, multivariate data analysis PCA was applied to reduce the number of variables and identify the number of loadings, which consist the hyperspectral Raman data. Based on the eigenvalues, the hyperspectral data can be described by two principal components (PCs). This is a typical observation in multivariate data analysis of Raman spectra, which leadsarbitrarily to the assumption that there areonly two components in the system, as the first PC corresponds to the features of the strongest spectral contributors.It can be clearly observed from Fig. 8b that and 1739 cm −1 respectively, confirm the homogeneity of the analysed samples. The Raman mapping analysis in Fig. 2b showed that in the concentration maps (200 × 200μm) corresp to PC1 and PC4, IND is uniformly distributed in the bulk across the scanned areas while the coloured areas overlap indicating the existence of a molecular dispersion.
Taste Masking Evaluation
Taste masking efficiency of the 3D Starmix® designs was of the utmost importance for the purpose of paediatric applications [35, 36] . We anticipated that the selection of the excipients and the HME processing will result in efficient masking of IND bitterness and increase the palatability of the printed designs. As shown in Fig. 9 the panel list evaluation revealed moderate bitterness for IND while slight and threshold for PEG and HPMCAS respectively. All 3D printed designs showed excellent taste masking with no bitterness at all and no aftertaste was reported. The masking effect is attributed to the drug -polymer interactions through H-bonding facilitated by HME processing [37] . The effective taste masking of the Starmix® designs suggests that 3D printed dosage forms can be successfully used in paediatric applications providing enhanced palatability.
Dissolution Studies
As HPMCAS dissolves at pH > 6 we anticipated IND release in the mouth. However, children are expected to chew the tablets for a few minutes (up to 2 min) and subsequently swallow them. For this reason, IND release was initially investigated similarly to Rachid et al. by using small volumes (2 ml) of simulated saliva (data not shown) [38] . The release of IND was found to vary from 8.0 -12 × 10
% which is negligible to cause any bitterness. These findings support the taste evaluation where the 3D printed tablets were found to mask IND bitternes.
In addition, the IND release profiles of four printed Starmix® designs were conducted in phosphate buffer (pH 7.4). The release profiles are illustrated in Fig. 10 where it can be observed that for each printed form more than 80% of the drug was released within the first 60 min while the Starmix® designs were completely dissolved.
The rapid IND release was facilitated by the fact that HPMCAS is highly soluble in pH > 6.0 and IND is molecularly dispersed within the printed forms. Interestingly, the release profiles of all Stramix® designs arevery similar and no significant difference was observed (p < 0.05). It is also important to mention that the optimized printing process achieved release patterns independent of the printed designs. This is a crucial feature for the development of oral dosage forms with multiple designs or patterns. However, the alignment of drug release from 3D printed dosage forms was also observed by Goyanes et al. where tablets of different shapes and similar weights provided similar drug release profiles [20] .
CONCLUSION
Starmix® designs were manufactured by using FDM 3D printing coupled with HME processing for the development of palatable paediatric dosage forms. FDM process was proved efficient in printing detailed Starmix® designs with high reproducibility, accuracy and content uniformity. Physicochemical characterisation studies showed that IND was molecularly dispersed in the HPMCAS matrix. The panel list taste evaluation showed excellent taste masking efficiency and hence enhanced palatability. The drug release profiles showed rapid IND release independent of the shape of printed design. Overall, we demonstrated that 3D printing can be used as an alternative manufacturing route for paediatric medicines.
